57 related articles for article (PubMed ID: 16197661)
1. Trospium and cognition in patients with late onset Alzheimer disease.
Isik AT; Celik T; Bozoglu E; Doruk H
J Nutr Health Aging; 2009 Oct; 13(8):672-6. PubMed ID: 19657549
[TBL] [Abstract][Full Text] [Related]
2. Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.
Tangwongchai S; Thavichachart N; Senanarong V; Poungvarin N; Phanthumchinda K; Praditsuwan R; Nidhinandana S; Chankrachang S
Am J Alzheimers Dis Other Demen; 2008 Dec-2009 Jan; 23(6):593-601. PubMed ID: 18845693
[TBL] [Abstract][Full Text] [Related]
3. Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia.
Droogsma E; van Asselt DZ; van Steijn JH; Schuur T; Huinink EJ
J Nutr Health Aging; 2013; 17(5):461-5. PubMed ID: 23636548
[TBL] [Abstract][Full Text] [Related]
4. An innovative approach to involve patients in measuring treatment effects in drug trials.
Kaduszkiewicz H
CMAJ; 2006 Apr; 174(8):1117-8. PubMed ID: 16554497
[No Abstract] [Full Text] [Related]
5. Professor Keith Andrew Wesnes (1950 to 2020).
Edgar CJ; Brooker H
Alzheimers Dement (Amst); 2020; 12(1):e12086. PubMed ID: 32995463
[No Abstract] [Full Text] [Related]
6. Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial.
Vila-Castelar C; Ly JJ; Kaplan L; Van Dyk K; Berger JT; Macina LO; Stewart JL; Foldi NS
Arch Clin Neuropsychol; 2019 May; 34(3):277-289. PubMed ID: 29635383
[TBL] [Abstract][Full Text] [Related]
7. Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials.
Goldberg TE; Harvey PD; Wesnes KA; Snyder PJ; Schneider LS
Alzheimers Dement (Amst); 2015 Mar; 1(1):103-11. PubMed ID: 27239497
[TBL] [Abstract][Full Text] [Related]
8. Predictors of decline in walking ability in community-dwelling Alzheimer's disease patients: Results from the 4-years prospective REAL.FR study.
Rolland Y; Cantet C; Barreto Pde S; Cesari M; Abellan van Kan G; Vellas B
Alzheimers Res Ther; 2013; 5(5):52. PubMed ID: 24517197
[TBL] [Abstract][Full Text] [Related]
9. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial.
Lanctôt KL; Chau SA; Herrmann N; Drye LT; Rosenberg PB; Scherer RW; Black SE; Vaidya V; Bachman DL; Mintzer JE
Int Psychogeriatr; 2014 Feb; 26(2):239-46. PubMed ID: 24169147
[TBL] [Abstract][Full Text] [Related]
10. A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.
Palmqvist S; Minthon L; Wattmo C; Londos E; Hansson O
Alzheimers Res Ther; 2010 Oct; 2(5):29. PubMed ID: 20950460
[TBL] [Abstract][Full Text] [Related]
11. Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.
Edgar CJ; Pace-Schott EF; Wesnes KA
Hum Psychopharmacol; 2009 Jul; 24(5):371-89. PubMed ID: 19565524
[TBL] [Abstract][Full Text] [Related]
12. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease.
Kadir A; Almkvist O; Wall A; Långström B; Nordberg A
Psychopharmacology (Berl); 2006 Nov; 188(4):509-20. PubMed ID: 16832659
[TBL] [Abstract][Full Text] [Related]
14. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.
Vellas B; Cunha L; Gertz HJ; De Deyn PP; Wesnes K; Hammond G; Schwalen S;
Curr Med Res Opin; 2005 Sep; 21(9):1423-9. PubMed ID: 16197661
[TBL] [Abstract][Full Text] [Related]
15. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
16. The effects of galantamine treatment on caregiver time in Alzheimer's disease.
Sano M; Wilcock GK; van Baelen B; Kavanagh S
Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127
[TBL] [Abstract][Full Text] [Related]
17. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.
Monsch AU; Giannakopoulos P;
Curr Med Res Opin; 2004 Jun; 20(6):931-8. PubMed ID: 15200752
[TBL] [Abstract][Full Text] [Related]
18. Galantamine: a review of its use in Alzheimer's disease and vascular dementia.
Corey-Bloom J
Int J Clin Pract; 2003 Apr; 57(3):219-23. PubMed ID: 12723727
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
